Projektdaten
A Randomized, Phase 2, Open-label Trial of TransCon TLR7/8 Agonist inCombination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransConIL-2 ?/?, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with StageIII-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Hochschule
Universitätsklinikum Jena
Fakultät/Einrichtung
Medizinische Fakultät
Förderkategorie
Auftragsforschung
Zeitraum
2024 - 2026
Drittmittelgeber
Syneos Health UK Limited
Stichwort
Bewilligungssumme, Auftragssumme
Kategorie 10.000,00 - 99.999,00 €
Abstract:
Phase 2, Open-label Study of TransCon IL-2 ?/? Monotherapy, TransCon IL-2 ?/? in Combination with TransCon TLR7/8 Agonist, TransCon TLR7/8 Agonist in Combination with Pembrolizumab, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)